Addyi

Valeant may be on the verge of a technical default as its lender demand not one but two pounds of flesh, it may be suffering imploding sales, it may have fired the entire salesforce for the female libido drug Addyi (which it acquired late last year), and it may be trying to pin all of its allegedly criminal book-cooking on its former CFO (who used to be a fromer head Goldman banker), the same CFO who refuses to resign from Valeant's board even though Valeant clearly wants him gone, but at least minutes ago, an ad hoc committee from Valeant's board (yes the same board where the former scapeg

It's been a terrible month for investors in Valeant (and Pershing Square) and it is about to get even worse following news that the outgoing CEO of the troubled company, which is under scrutiny for dramatically hiking the price of older drugs, has been summoned to testify at a U.S. congressional hearing on April 27, the panel said on Monday.